Verified Nov 2026
Other
·
Newport Beach, California
·
Since 2014
Evolus, Inc. is a publicly traded medical aesthetics company headquartered in Newport Beach, California, founded in 2014. It has 200-500 employees and reported revenue in the $297.2M band. The company develops injectable aesthetic treatments for facial lines and contours, including its Jeuveau botulinum toxin product, and serves practitioners and consumers in the self-pay aesthetic market across the United States, Canada, Europe, and Australia. Its shares trade on NASDAQ under the ticker EOLS.
Evolus at a glance
Revenue
297.2M
Employees
200-500
Founded
2014
Headquarters
Newport Beach, California
Ownership
Publicly traded (NASDAQ: EOLS)
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Consumer Goods
Overview
Evolus, Inc. is a publicly traded medical aesthetics company headquartered in Newport Beach, California, founded in 2014. It has 200-500 employees and reported revenue in the $297.2M band. The company develops injectable aesthetic treatments for facial lines and contours, including its Jeuveau botulinum toxin product, and serves practitioners and consumers in the self-pay aesthetic market across the United States, Canada, Europe, and Australia. Its shares trade on NASDAQ under the ticker EOLS.
At a glance
Attribute | Detail |
|---|---|
Founded | 2014 |
Headquarters | Newport Beach, California |
Employees | 200-500 |
Revenue | 297.2M |
Ownership | Publicly traded (NASDAQ: EOLS) |
What Evolus makes
The company markets Jeuveau, a botulinum toxin type A product for moderate to severe frown lines in adults, and is developing Evolysse, a hyaluronic acid gel line for facial contouring.
Latest developments
2026-11-05 — Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook - BioSpace (biospace.com)
2026-10-14 — Evolus, Inc. - Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program (evolus.com)
2026-08-05 — Evolus, Inc. - Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook (evolus.com)
2026-08-04 — Evolus, Inc. - Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand (evolus.com)
2026-07-08 — Evolus, Inc. - Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality (evolus.com)
2025-07-09 — Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France (businesswire.com)
Facilities
Evolus is headquartered in Newport Beach, California. Public sources also reference these locations:
South Korea — fiercepharma.com
Company details
Evolus is publicly listed on NASDAQ (ticker EOLS) and expanded its portfolio in July 2026 through a partnership with IBSA to commercialize Profhilo in the United States. Evolus was founded in 2014, has an estimated 200-500 employees, and is headquartered in Newport Beach, California.
Frequently asked questions
What does Evolus do?
Evolus, Inc. is a publicly traded medical aesthetics company headquartered in Newport Beach, California, founded in 2014. It has 200-500 employees and reported revenue in the $297.2M band. The company develops injectable aesthetic treatments for facial lines and contours, including its Jeuveau botulinum toxin product, and serves practitioners and consumers in the self-pay aesthetic market across the United States, Canada, Europe, and Australia. Its shares trade on NASDAQ under the ticker EOLS.
Where is Evolus headquartered?
Evolus is headquartered in Newport Beach, California (520 Newport Center Drive, Newport Beach, California, 92660).
When was Evolus founded?
Evolus was founded in 2014.
How big is Evolus?
Evolus has an estimated 200-500 employees, with revenue in the 297.2M range.
Is Evolus publicly traded?
Publicly traded (NASDAQ: EOLS). Public financial figures are drawn from its filings.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.